Search Results

You are looking at 11 - 20 of 793 items for :

  • "screening" x
Clear All
Full access

Rebecca P. Petersen and David H. Harpole Jr.

. 6. Fontana RS Sanderson DR Woolner LB . Lung cancer screening: the Mayo program . J Occup Med 1986 ; 28 : 746 – 750 . 7. Melamed MR Flehinger BJ Zaman MB . Screening for early lung cancer . Chest 1984 ; 86 : 44 – 53 . 8

Full access

Huong T. Le-Petross

BRCA2 mutation carriers . Cancer Res 2006 ; 66 : 1866 – 1872 . 8. Lehman CD Blume JD Weatherall P . Screening women at high risk for breast cancer with mammography and magnetic resonance imaging . Cancer 2005 ; 103 : 1898 – 1905

Full access

Edward E. Partridge, Nadeem Abu-Rustum, Anna Giuliano, Stewart Massad, Joan McClure, Mary Dwyer and Miranda Hughes

recent changes to cervical cancer screening recommendations and management of abnormal screening test results Describe the rationale behind the recent changes in management for cervical cancer screening Overview Cervical cytology screening

Full access

Sean Dineen, Patrick M. Lynch, Miguel A. Rodriguez-Bigas, Sarah Bannon, Melissa Taggart, Colleen Reeves, Cathy Modaro, Michael Overman, George J. Chang, John M. Skibber and Y. Nancy You

analytic models. 8 , 13 , 14 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CRC Screening have evolved to place increasing emphasis on molecular testing for detection of hereditary cancer syndromes, specifically testing for MMR

Full access

William J. Catalona and Stacy Loeb

T he prostate-specific antigen (PSA) blood test is the foundation for modern prostate cancer (CaP) screening. Initially it was used in forensic medicine. The subsequent discovery that it could be measured in serum, and that serum levels increase

Full access

Heather Hampel

their relatives to undergo genetic counseling and testing to learn if they too are at increased risk for cancer and could benefit from intensive cancer surveillance. The costs of screening can be offset by the benefits of cancer prevention in the patient

Full access

Jonathan Potack and Steven H. Itzkowitz

Colorectal cancer (CRC) is a very common and often fatal cancer in the United States and worldwide. Screening has been shown to be highly effective in preventing the incidence and subsequent mortality from CRC, and has been endorsed by all major

Full access

Brady J. McKee, Shawn Regis, Andrea K. Borondy-Kitts, Jeffrey A. Hashim, Robert J. French Jr, Christoph Wald and Andrea B. McKee

Background NCCN, the Centers for Medicare & Medicaid Services (CMS), and the US Preventive Services Task Force (USPSTF) recommend annual CT lung screening (CTLS) for current and former heavy smokers meeting the National Lung Screening Trial

Full access

Matthew Loscalzo, Karen Clark, Jeff Dillehunt, Redmond Rinehart, Rex Strowbridge and Daniel Smith

-offsetting advantages of addressing biopsychosocial issues, despite the effort and cost of establishing an automated screening/triage system. 3 – 5 These include cost benefits to hospitals providing psychosocial care, 3 and the potential for psychological distress

Full access

Randall W. Burt, James S. Barthel, Kelli Bullard Dunn, Donald S. David, Ernesto Drelichman, James M. Ford, Francis M. Giardiello, Stephen B. Gruber, Amy L. Halverson, Stanley R. Hamilton, Mohammad K. Ismail, Kory Jasperson, Audrey J. Lazenby, Patrick M. Lynch, Edward W. Martin Jr., Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman and David Weinberg

Colorectal Cancer Screening Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN